Additional Relevant Details Data from the study revealed that there was a slowing in the rate of change in the Total Motor Score (TMS) component of the Unified Huntington's Disease Rating Scale (UHDRS) at 36 months of treatment favoring earlier RP103 treatment (RP103-RP103) versus delayed start of RP103 treatment (placebo-RP103). The 25% treatment effect in TMS favoring subjects treated with RP103 for the full 36 months as compared to the placebo/RP103 arm, while not statistically significant, is regarded by clinical leaders in the field as clinically meaningful. The TMS data were consistent with observed effects in key functional measures including Total Functional Capacity (TFC) and Independence Scale. There was statistically significant improvement in the Independence Scale.